系统性红斑狼疮与B细胞淋巴瘤患者CD19靶向CAR-T细胞治疗安全性比较
该研究比较了系统性红斑狼疮(SLE)与B细胞非霍奇金淋巴瘤(B-NHL)患者接受CD19靶向CAR-T细胞治疗后的毒性特征。尽管CAR-T细胞扩增相似,SLE患者的细胞因子释放综合征、免疫效应细胞相关神经毒性综合征和免疫效应细胞相关血液毒性发生率及严重程度均较低,且血液毒性持续时间更短、免疫重建更快。结果表明SLE患者接受CAR-T治疗的安全性更优。
要点
- SLE患者CAR-T治疗后细胞因子释放综合征、神经毒性及血液毒性发生率低于B-NHL。
- SLE患者血液毒性持续时间更短,血小板计数接近正常,尽管中性粒细胞最低值更低。
- SLE患者CAR-T细胞持久性较短,常规T细胞和B细胞重建更快。
核心结论
- 相似的淋巴细胞清除和CAR-T细胞药代动力学导致SLE与B-NHL患者出现不同的毒性特征,SLE患者接受CAR-T治疗的安全性更优,适应性免疫系统恢复更快。
研究设计与样本
- 研究比较了接受CD19靶向CAR-T细胞治疗的SLE患者与复发/难治性B细胞非霍奇金淋巴瘤患者的CAR-T细胞动力学及治疗相关副作用。
主要发现
- 与B-NHL患者相比,SLE患者的细胞因子释放综合征、免疫效应细胞相关神经毒性综合征和免疫效应细胞相关血液毒性发生率和严重程度均较低,且血液毒性持续时间更短。
- SLE患者治疗后中性粒细胞最低值更低,但血小板计数保持接近正常。
- SLE患者CAR-T细胞持久性持续较短,常规T细胞和B细胞重建更快。
- 在两个队列中,B细胞重建与功能性CD4+ T细胞恢复相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19-directed chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and recently showed effects in autoimmune diseases, such as systemic lupus erythematosus (SLE). Despite high levels of inflammation, toxicity seemed to differ between patients with SLE and B-NHL. We therefore compared the CAR T-cell kinetics and treatment-related side effects to better define the toxicity profiles. In contrast with the similar CAR T-cell expansion, patients with SLE revealed a lower incidence and severity of cytokine-release syndrome, immune effector cell-associated neurotoxicity syndrome, and immune effector cell-associated hematotoxicity. Although the neutrophil nadir was lower in patients with SLE after therapy, the platelet counts remained close to normal and hematotoxicity was shorter in SLE than B-NHL. The reduced hematotoxicity correlated with lower acute-phase inflammation, better hematologic reserve before CAR T-cell therapy, and distinct serum cytokine profiles. Interestingly, CAR T-cell persistence was consistently shorter, and the reconstitution of conventional T and B cells was faster in SLE. In both cohorts, B-cell reconstitution correlated with functional CD4+ T-cell recovery, indicating a general biologic process of hematopoietic and immune system regeneration. In summary, similar lymphodepletion and CAR T-cell pharmacokinetics led to distinct toxicity, demonstrating that CAR T-cell therapy had a favorable side-effect profile in SLE, including faster recovery of the adaptive immune system.
引用
- Müller F, Schwingen NR, Hagen M, et al. Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma. Blood. 2025. PMID: 40504989. doi:10.1182/blood.2025028375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。